CMS’ proposed changes to the Medicare Shared Savings Program (MSSP) doesn’t represent a major shift in policy stance toward accountable care organizations (ACOs), said Joe Antos, PhD, the Wilson H. Taylor Resident Scholar in Health Care and Retirement Policy at the American Enterprise Institute.
CMS’ proposed changes to the Medicare Shared Savings Program (MSSP) doesn’t represent a major shift in policy stance toward accountable care organizations (ACOs), said Joe Antos, PhD, the Wilson H. Taylor Resident Scholar in Health Care and Retirement Policy at the American Enterprise Institute.
Transcript
If the proposed CMS changes to the MSSP are expected to make fewer ACOs participate, do you think the proposal will affect the ACO movement?
I wouldn’t say that this is a major change in policy with regard to ACOs. The current administration has clearly accepted the concept of ACOs, they’re clearly trying to promote them in a way.
I would say that Andy Slavitt, who was the CMS administrator under [President] Obama, said something to the effect of “yeah, there should be a time limit and if you’re not successful within a reasonable time limit, then you should go. Because it’s not going to work out for you.” So, I think that’s kind of a hard-eyed business look at this. But I don’t think this is a major change in policy.
They’re going to have to do other things to either strongly promote ACOs or strongly discourage them. I think one of the things that would promote ACOs or promote movement toward a more sensible approach to delivery, in general, would be to follow some of MedPAC [Medicare Payment Advisory Commission]’s suggestions with regard to fixing MIPS [Merit-based Incentive Payment System] and fixing MACRA [Medicare Access and CHIP Reauthorization Act], which is a problem all by itself.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
Driving Value via Outcomes-Based Pricing and EHR Interoperability: Tyler Sandahl, PharmD
July 7th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for chimeric antigen receptor T-cell and bispecific therapies and the need for improved data sharing in cancer care.
Read More
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity
July 1st 2025Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.
Read More